Unlock stock picks and a broker-level newsfeed that powers Wall Street.
ASX Penny Stock Spotlight Algorae Pharmaceuticals And Two More Companies

In This Article:

The Australian market has recently experienced a downturn, with the ASX 200 setting a new 20-day low, influenced by global trade uncertainties and flat commodity prices. Despite these challenges, certain investment opportunities remain appealing, particularly in sectors like Utilities and Health Care that have shown resilience. Penny stocks may seem like an outdated concept, but they continue to offer potential for growth at lower price points when backed by strong financials. In this article, we explore three such penny stocks on the ASX that stand out for their robust balance sheets and promising prospects.

Top 10 Penny Stocks In Australia

Name

Share Price

Market Cap

Financial Health Rating

Embark Early Education (ASX:EVO)

A$0.79

A$144.95M

★★★★☆☆

Perenti (ASX:PRN)

A$1.16

A$1.07B

★★★★★★

Austin Engineering (ASX:ANG)

A$0.45

A$279.07M

★★★★★☆

IVE Group (ASX:IGL)

A$2.34

A$362.44M

★★★★☆☆

GTN (ASX:GTN)

A$0.54

A$106.04M

★★★★★★

Helloworld Travel (ASX:HLO)

A$2.05

A$333.78M

★★★★★★

Southern Cross Electrical Engineering (ASX:SXE)

A$1.745

A$461.15M

★★★★★★

Bisalloy Steel Group (ASX:BIS)

A$3.21

A$153.77M

★★★★★★

Dusk Group (ASX:DSK)

A$1.03

A$64.14M

★★★★★★

EZZ Life Science Holdings (ASX:EZZ)

A$2.00

A$94.35M

★★★★★★

Click here to see the full list of 1,034 stocks from our ASX Penny Stocks screener.

Let's explore several standout options from the results in the screener.

Algorae Pharmaceuticals

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Algorae Pharmaceuticals Limited is a pharmaceutical development company focused on the research and development of living cells technologies primarily in New Zealand, with a market cap of A$11.81 million.

Operations: The company's revenue segment consists of A$0.13 million from its research and development activities in living cell technologies.

Market Cap: A$11.81M

Algorae Pharmaceuticals, with a market cap of A$11.81 million, is pre-revenue and focuses on the research and development of living cell technologies. Despite its unprofitability and negative return on equity, the company benefits from being debt-free for five years and has short-term assets exceeding liabilities by a significant margin. The management team is relatively new, with an average tenure of 1.6 years, indicating potential for strategic shifts. While its share price has been highly volatile recently, Algorae maintains a cash runway sufficient for over a year based on current free cash flow levels without shareholder dilution in the past year.